Product Overview
Purecrest combines DPP-4 inhibitor and SGLT2 inhibitor mechanisms for comprehensive glucose management with renal and cardiovascular benefits.
Composition
- Linagliptin - DPP-4 inhibitor
- Dapagliflozin - SGLT2 inhibitor
Indications
- Type 2 diabetes mellitus glucose control
- Inadequate glucose control on monotherapy
- Cardiovascular risk reduction
- Renal protection in diabetes
- Heart failure management
Marketed By
Vee Medi Biotech